GlassScriptPhysician profile
Michelle Rohde
NPI 1154957330
$2,277.75
in general payments reported to CMS, 2019-2025
27 companies · $53.20 in 2025
The $53.20 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2023: $1,310 · 2024: $798 · 2025: $53.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.15 | 2023-2024 | |
| Pfizer INC. | $344.85 | 2023-2024 | |
| Lilly USA, LLC | $195.67 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $178.94 | 2023-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $98.37 | 2023 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $92.62 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $87.89 | 2023-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $87.42 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.56 | 2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $67.31 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.32 | 2021-2023 | Trintellix, Glassia |
| Optinose US, INC. | $45.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.73 | 2024 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $41.63 | 2024 | |
| Merck Sharp & Dohme LLC | $39.32 | 2023 | Gardasil 9, Vaxelis, Vaxneuvance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $36.06 | 2025 | |
| Currax Pharmaceuticals LLC | $30.83 | 2023 | Contrave, Onzetra Xsail |
| Esperion Therapeutics, INC. | $28.47 | 2023-2024 | Nexletol |
| Seqirus USA INC | $25.96 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Dexcom, INC. | $24.17 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $21.82 | 2024 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $19.91 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.82 | 2021 | |
| Hologic Sales and Service, LLC | $16.22 | 2024 | Aptima |
| Phathom Pharmaceuticals, INC. | $13.84 | 2024 | Voquezna |
| Amgen INC. | $13.81 | 2024 | Repatha, Otezla |
| Cranial Technologies, INC | $13.15 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Rohde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.